Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes
Memorial Sloan Kettering Cancer Center · Cornell University
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
444
total citations
- FWCI
- 35.05
- Percentile
- 100%
- References
- 31
Citations per year
Authors
17Topics & keywords
Topics
Keywords
- Medicine
- Mutant
- Oncology
- Lung
- Transformation (genetics)
- Internal medicine
- Cancer research
- Pathology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- FFFoundation for the National Institutes of HealthAwards: P01 CA129243, P30 CA008748, T32 CA009207
- AAmgen
- BSBristol-Myers Squibb
- IBInternational Business Machines Corporation
- PPfizer
- BBayer
- NNovartis
- NCNorth Carolina GlaxoSmithKline Foundation
- CCelgene
- AAbbVie
- UOUniversity of Rochester
- RPRegeneron Pharmaceuticals
- SOSociety of Memorial Sloan Kettering
- NINational Institutes of HealthAwards: P30 CA008748, P01 CA129243, T32 CA009207
- GGenentech
- HTHelsinn Therapeutics
- MSMerck Sharp and Dohme
- DSDaiichi Sankyo Company
- NCNational Cancer Institute